Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases
https://doi.org/10.21518/2079-701X-2021-10-108-111
Abstract
The COVID-19 pandemic was announced in 2020, and many professional medical societies had to review their algorithms for the management of high-risk patients. In addition to risk factors such as overweight, age over 65 years, cardiovascular disease, diabetes mellitus, and bronchial asthma, other chronic diseases should also be emphasized, taking into account possible immunosuppressive therapy. This publication presents two clinical cases of COVID-19 infection in patients with multiple sclerosis treated with ocrelizumab. During the course of the disease, both patients developed a cytokine storm and were treated with IL-6 blockers. Both cases ended with recovery and a subsequent return to anti-B-cell therapy. Given the mechanism of action of ocrelizumab, there are higher risks of infectious complications, including with COVID-19, but mortality is not higher than the population average. The information published to date may serve as a reason to consider the use of extended dosing intervals to minimize the possible risks of COVID-19 infection, which are probably highest in the first months after infusion.
About the Authors
E. V. Popova
City Clinical Hospital No. 24
Russian Federation
Russian Federation
Ekaterina V. Popova, Dr. Sci. (Med.), Head of the Interdistrict Department of Multiple Sclerosis, Head of Therapeutic Department 210/212 of the Exhibition of Achievements of the National Economy (EANE) Reserve Hospital.
10, Pistsovaya St., Moscow, 127015
M. I. Alexandrov
City Clinical Hospital No. 24
Russian Federation
Russian Federation
Maxim I.Alexandrov, Head of the Department of Reanimation and Intensive Care of the Perinatal Center, Head of the Reanimation and Intensive Department of the 306 EANE Reserve Hospital.
10, Pistsovaya St., Moscow, 127015
I. A. Trubnikova
City Clinical Hospital No. 24
Russian Federation
Russian Federation
Inessa A. Trubnikova, Cand. Sci. (Med.), Head of the Therapeutic Department, Deputy Chief Physician for Therapy of the EANE Reserve Hospital.
10, Pistsovaya St., Moscow, 127015
S. R. Zeynalova
City Clinical Hospital No. 24
Russian Federation
Russian Federation
Svetlana R. Zeynalova, Cand. Sci. (Med.), Deputy Chief Physician for Clinical Expert Work, Head of the Reserve Hospital of EANE Reserve Hospital.
10, Pistsovaya St., Moscow, 127015
References
1. Zhou F., Yu T., Du R., Fan G., Liu Y, Liu Z. et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3.
2. Guan WJ., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032.
3. Luna G., Alping P., Burman J., Fink K., Fogdell-Hahn A., Gunnarsson M. et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020;77(2):184-191. https://doi.org/10.1001/]amaneurol.2019.3365.
4. Karamyan A., Dunser M.W., Wiebe DJ., Pilz G., Wipfler P, Chroust V. et al. Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study. PLoS One. 2016;11(5):e0155795. https://doi.org/10.1371/journal.pone.0155795.
5. Thompson AJ., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G. et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol. 2018;17(2):162-173. https://doi.org/10.1016/S1474-4422(17)30470-2.
6. Avdeev S.N., Adamyan L.V., Alekseeva E.I., Bagnenko S.F., Baranov A.A., Baranova N.N. et al. Temporary Guidelines. Prevention, Diagnosis and Treatment of New Coronavirus Infection (COVID-19). Version 9 (10/26/2020). Moscow: Ministry of Health of the Russian Federation; 2020. 236 p. (In Russ.) Available at: https://static-0.minzdrav.gov.ru/system/attachments/attach-es/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf.
7. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P, Lublin F.D. et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50(1):121-127. https://doi.org/10.1002/ana.1032.
8. Giovannoni G., Hawkes C., Lechner-Scott J., Levy M., Waubant E., Gold J. The COVID-19 Pandemic and the Use of MS Disease-Modifying Therapies. Mult Scler Relat Disord. 2020;39:102073. https://doi.org/10.1016/j.msard.2020.102073.
9. Barzegar M., Mirmosayyeb O., Nehzat N., Sarrafi R., Khorvash F., Maghzi A.H., Shaygannejad V. COVID-19 Infection in a Patient with Multiple Sclerosis Treated with Fingolimod. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e753. https://doi.org/10.1212/NXI.0000000000000753.
10. Berger J.R., Brandstadter R., Bar-Or A. COVID-19 and MS Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e761. https://doi.org/10.1212/NXI.0000000000000761.
11. Al-Ani M., Elemam N.M., Hundt J.E., Maghazachi AA. Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection? Infect Drug Resist. 2020;13:3243-3254. https://doi.org/10.2147/IDR.S269797.
12. Wolinsky J.S., Arnold D.L., Brochet B., Hartung H.P, Montalban X., Naismith R.T. et al. Long-Term Follow-Up from the ORATORIO Trial of Ocrelizumab for Primary Progressive Multiple Sclerosis: A Post-Hoc Analysis from the Ongoing Open-Label Extension of the Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Neurol. 2020;19(12):998-1009. https://doi.org/10.1016/S1474-4422(20)30342-2.
13. Louapre C., Collongues N., Stankoff B., Giannesini C., Papeix C., Bensa C. et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020;77(9):1079-1088. https://doi.org/10.1001/jamaneurol.2020.2581.
14. Montero-Escribano P, Matias-Guiu J., Gomez-Iglesias P, Porta-Etessam J., Pytel V., Matias-Guiu JA.. Anti-CD20 and COVID-19 in Multiple Sclerosis and Related Disorders: A Case Series of 60 Patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. https://doi.org/10.1016/j.msard.2020.102185.
15. Chaudhry F., Bulka H., Rathnam A.S., Said O.M., Lin J., Lorigan H. et al. COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection. J Neurol Sci. 2020;418:117147. https://doi.org/10.1016/j.jns.2020.117147.
16. Kuijpers T.W., Bende R.J., Baars P.A., Grummels A., Derks I.A., Dolman K.M. et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120(1):214-222. https://doi.org/10.1172/JCI40231.
17. Peeters L.M., Parciak T., Walton C., Geys L., Moreau Y., De Brouwer E. et al. COVID-19 in People with Multiple Sclerosis: A Global Data Sharing Initiative. Mult Scler. 2020;26(10):1157-1162. https://doi.org/10.1177/1352458520941485.
Review
For citations:
Popova EV, Alexandrov MI, Trubnikova IA, Zeynalova SR. Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases. Meditsinskiy sovet = Medical Council. 2021;(10):108-111. (In Russ.) https://doi.org/10.21518/2079-701X-2021-10-108-111
Views:
534
Email this article 